Alterations in brain synaptic proteins and mRNAs in mood disorders: a systematic review and meta-analysis of postmortem brain studies

2022 ◽  
Author(s):  
Edison Leung ◽  
Ethan W. Lau ◽  
Andi Liang ◽  
Constanza de Dios ◽  
Robert Suchting ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mood Disorders ◽  
Meta Analysis ◽  
Synaptic Proteins ◽  
Postmortem Brain

scholarly journals Magnesium and mood disorders: systematic review and meta-analysis

BJPsych Open ◽  
2018 ◽  
Vol 4 (4) ◽  
pp. 167-179 ◽  
Author(s):  
Danny Phelan ◽  
Patricio Molero ◽  
Miguel A. Martínez-González ◽  
Marc Molendijk
Keyword(s):  
Systematic Review ◽  
Mood Disorders ◽  
Symptom Severity ◽  
Odds Ratio ◽  
Potential Role ◽  
Meta Analysis ◽  
Blood Levels ◽  
Cross Sectional ◽  
Bodily Fluids ◽  
Meta Analyses

BackgroundMagnesium (Mg2+) has received considerable attention with regards to its potential role in the pathophysiology of the mood disorders, but the available evidence seems inconclusive.AimsTo review and quantitatively summarise the human literature on Mg2+intake and Mg2+blood levels in the mood disorders and the effects of Mg2+supplements on mood.MethodSystematic review and meta-analyses.ResultsAdherence to a Mg2+-rich diet was negatively associated with depression in cross-sectional (odds ratio = 0.66) but not in prospective studies. Mg2+levels in bodily fluids were on average higher in patients with a mood disorder (Hedge'sg = 0.19), but only in patients treated with antidepressants and/or mood stabilisers. There was no evident association between Mg2+levels and symptom severity. Mg2+supplementation was associated with a decline in depressive symptoms in uncontrolled (g = −1.60) but not in placebo-controlled trials (g = −0.21).ConclusionOur results provide little evidence for the involvement of Mg2+in the mood disorders.Declaration of interestNone.

scholarly journals Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

BMJ ◽  
2013 ◽  
Vol 346 (jun27 4) ◽  
pp. f3646-f3646 ◽  
Author(s):  
A. Cipriani ◽  
K. Hawton ◽  
S. Stockton ◽  
J. R. Geddes
Keyword(s):  
Systematic Review ◽  
Mood Disorders ◽  
Meta Analysis

scholarly journals The risk of offspring mood and anxiety disorders in the context of prenatal maternal somatic diseases: a systematic review and meta-analysis

2022 ◽  
Vol 31 ◽  
Author(s):  
Xiayu Gong ◽  
Zhixin Fan ◽  
Hanfang Xu ◽  
Hanzhang Wang ◽  
Ningxi Zeng ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Anxiety Disorders ◽  
Mood Disorders ◽  
Maternal Obesity ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Mood And Anxiety Disorders ◽  
Increased Risk ◽  
Somatic Diseases

Abstract Aims The importance of prenatal maternal somatic diseases for offspring mood and anxiety disorders may be overlooked or undervalued. We conducted the first systematic review and meta-analysis assessing the risk of offspring mood and anxiety disorders in the context of prenatal maternal somatic diseases. Methods We screened articles indexed in Embase (including Embase, MEDLINE, PubMed-not-MEDLINE), PsycARTICLES and PsycINFO databases up to August 2021. 21 studies were included. We examined the overall associations between prenatal maternal somatic diseases and offspring mood/anxiety disorders. Analyses were stratified according to maternal somatic diseases and follow-up duration. Results We observed an increased risk of mood and anxiety disorders in the context of prenatal maternal somatic diseases [relative risk (RR) = 1.26; 95% confidence interval (CI) 1.15–1.37, RR = 1.31; 95% CI 1.24–1.38]; maternal obesity(RR = 1.92; 95% CI 1.72–2.11), hypertensive disorders (RR = 1.49; 95% CI 1.11–1.86) and infertility (RR = 1.26, 95% CI 1.14–1.39) were risk factors for mood disorders; maternal polycystic ovary syndrome (RR = 1.61; 95% CI 1.42–1.80), severe obesity (RR = 1.56; 95% CI 1.44–1.68) and moderate obesity (RR = 1.36; 95% CI 1.28–1.44) were risk factors for anxiety disorders. Prenatal maternal somatic diseases increased the risk of mood disorders in childhood and adulthood (RR = 1.71; 95% CI 1.34–2.09/RR = 1.19; 95% CI 1.09–1.30), as well as the risk of anxiety disorders in adulthood (RR = 1.33; 95% CI 1.26–1.41). Conclusion The results indicate that prenatal maternal somatic diseases are associated with offspring mood and anxiety disorders, and that the associations may be long-lasting.

scholarly journals Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies

2018 ◽  
Vol 92 ◽  
pp. 477-485 ◽  
Author(s):  
Danilo Arnone ◽  
Smita Saraykar ◽  
Haitham Salem ◽  
Antonio L. Teixeira ◽  
Robert Dantzer ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mood Disorders ◽  
Clinical Studies ◽  
Meta Analysis ◽  
Kynurenine Pathway

scholarly journals The Association Between Borna Disease Virus and Mood Disorders: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 5 (2) ◽  
Author(s):  
Milad Azami ◽  
Farid Azizi Jalilian ◽  
Mohammad Reza Adhami Mojarad ◽  
Younes Mohammadi ◽  
Zeinab Tardeh
Keyword(s):  
Systematic Review ◽  
Mood Disorders ◽  
Disease Virus ◽  
Meta Analysis ◽  
Borna Disease Virus ◽  
Borna Disease

Actigraphy for evaluation of mood disorders: A systematic review and meta-analysis

2019 ◽  
Vol 253 ◽  
pp. 257-269 ◽  
Author(s):  
Yuuki Tazawa ◽  
Masataka Wada ◽  
Yasue Mitsukura ◽  
Akihiro Takamiya ◽  
Momoko Kitazawa ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mood Disorders ◽  
Meta Analysis

scholarly journals Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis

BMJ Open ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. e025145
Author(s):  
Bianca E Kavanagh ◽  
Sharon Lee Brennan-Olsen ◽  
Alyna Turner ◽  
Olivia M Dean ◽  
Michael Berk ◽  
...  
Keyword(s):  
Systematic Review ◽  
Personality Disorder ◽  
Mood Disorders ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Controlled Trials ◽  
Pharmacological Interventions ◽  
Randomised Controlled

IntroductionRemission rates for mood disorders, including depressive and bipolar disorders, remain relatively low despite available treatments, and many patients fail to respond adequately to these interventions. Evidence suggests that personality disorder may play a role in poor outcomes. Although personality disorders are common in patients with mood disorders, it remains unknown whether personality disorder affects treatment outcomes in mood disorders. We aim to review currently available evidence regarding the role of personality disorder on pharmacological interventions in randomised controlled trials for adults with mood disorders.Methods and analysisA systematic search of Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com, PubMed via PubMed, EMBASE via embase.com, PsycINFO via Ebsco and CINAHL Complete via Ebsco databases will be conducted to identify randomised controlled trials that have investigated pharmacological interventions in participants aged 18 years or older for mood disorders (ie, depressive disorders and bipolar spectrum disorders) and have also included assessment of personality disorder. One reviewer will screen studies against the predetermined eligibility criteria, and a second reviewer will confirm eligible studies. Data will be extracted by two independent reviewers. Methodological quality and risk of bias will be assessed using the Cochrane Risk of Bias tool. A systematic review, and if sufficient evidence is identified, a meta-analysis will be completed. Meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. A random effects model will be employed and statistical heterogeneity will be evaluated using the I2 statistic. Prespecified subgroup analyses will be completed.Ethics and disseminationAs this systematic review will use published data, ethics permission will not be required. The outcomes of this systematic review will be published in a relevant scientific journal and presented at a research conference.Trial registration numberCRD42018089279.

Sign in / Sign up

Export Citation Format

Share Document